The Senate Judiciary Committee Subcommittee on Competition Policy, Antitrust, and Consumer Rights yesterday held a hearing on surging drug prices and anticompetitive conduct in the pharmaceutical industry.

Committee members and witnesses described how drug companies misuse patents and rebates to prevent competition and increase prices. 

“Drugs don’t work if people can’t afford them,” said David Mitchell, founder of Patients for Affordable Drugs and a cancer patient, noting that a drug for which he might be a candidate carries a list price of $419,500. 

Also testifying were representatives from the Washington Center for Equitable Growth, Mercatus Center at George Mason University, Pharmaceutical Research and Manufacturers of America, and biologics maker Fresenius Kabi.
 

Related News Articles

Headline
The AHA July 2 expressed support for the Drug-Price Transparency for Consumers Act of 2021 (S.2304).    “America’s hospitals and health systems are…
Headline
A new study demonstrates the cost to the U.S. health care system from an anti-competitive tactic known as “product hopping,” which involves a brand name drug…
Headline
The California Office of Statewide Health Planning and Development recently released the nation’s first mandatory data on wholesale acquisition cost increases…
Blog
A recent report from UnitedHealth comparing specialty drug spending in hospitals and independent physician offices fails to account for critical differences…
Headline
The House Energy and Commerce Committee today approved legislation to address surprise medical bills and Medicaid disproportionate share hospital cuts.  …
Headline
A federal judge yesterday struck down a Centers for Medicare & Medicaid Services final rule requiring drug companies to include list prices in direct-to-…